2. Search Result
Search Result
Results for "

Thrombi

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

2

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3012
    Cathepsin G

    		Cathepsin ERK p38 MAPK PKC Protease Activated Receptor (PAR) MMP Inflammation/Immunology
    Cathepsin G is a pH-dependent serine protease. Cathepsin G hydrolyzes diverse synthetic and protein substrates and remodels extracellular matrix. Cathepsin G exerts immunomodulatory effects via recruiting phagocytes, enhancing T cell motility, activating ERK1/2 and p38 MAPK signaling, and mediating PKCζ membrane translocation. Cathepsin G regulates inflammatory responses by cleaving inflammatory mediators. Cathepsin G participates in vascular regulation by converting angiotensin I to angiotensin II. Cathepsin G induces PAR4-dependent platelet activation, facilitates platelet-neutrophil aggregation, and mediates VITT-related NETosis, thrombus formation. Cathepsin G can be used for the research of immune thrombotic thrombocytopenia, cardiovascular disease, and select autoimmune and inflammatory diseases .
    Cathepsin G
  • HY-177580
    GP1 precursor

    		Integrin Cardiovascular Disease
    GP1 precursor has high affinity to GPIIb/IIIa receptors of activated platelets. GP1 precursor can be radiolabeled with [ 18F] and used as a PET Tracer for visualizing active platelet aggregation at the molecular level. GP1 precursor can be used for the detection of Thrombi .
    GP1 precursor
  • HY-107590
    GR144053 trihydrochloride

    		Integrin Cardiovascular Disease
    GR 144053 trihydrochloride is a selective and non-peptic GPIIb/IIIa inhibitor (IC50=37 nM) .
    GR144053 trihydrochloride
  • HY-P3082
    SKF 106760

    		Endogenous Metabolite Cardiovascular Disease
    SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .
    SKF 106760
  • HY-113769
    WB 3559 A

    		PAI-1 Cardiovascular Disease
    WB 3559 A is a fibrinolytic plasminogen activator. WB 3559 A accelerates the conversion of plasminogen to plasmin and directly degrades fibrin in thrombi. WB 3559 A is promising for research of acute thrombotic diseases (e.g., myocardial infarction, pulmonary embolism) .
    WB 3559 A
  • HY-182415
    RX-RA-69

    		Phosphodiesterase (PDE) Cardiovascular Disease Cancer
    RX-RA-69 is an orally active platelet phosphodiesterase (PDE) inhibitor with a IC50 of 1 nM. RX-RA-69 elevates cAMP levels in platelets, exerts anti-aggregatory effects, and inhibits the formation of coronary platelet thrombi. RX-RA-69 exhibits anti-metastatic activity in a mouse Lewis lung cancer model. RX-RA-69 can be used in research related to coronary platelet thrombi and Lewis lung cancer .
    RX-RA-69

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: